Reported 9 months ago
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, following previous launches in the United States and Japan. Leqembi is the first Alzheimer's treatment proven to alter the course of the disease by removing beta amyloid from the brain. The drug is priced at 2,508 yuan ($345.04) for a 200 mg vial initially and will receive partial coverage by a Chinese medical insurance firm. More convenient Alzheimer's blood tests expected in 2025 could further expand the drug's reach in China, where there are an estimated 17 million people with early-stage Alzheimer's.
Source: YAHOO